US FDA approves new use for Reyataz in HIV
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's HIV protease inhibitor Reyataz (atazanavir sulfate) has been approved by the US FDAfor previously untreated HIV-1 infected patients in a 300mg once-daily dose, boosted with 100mg ritonavir and used as part of combination therapy.